



## ADULT MEDICATION GUIDELINE

# REMIFENTANIL

**Scope (Staff):** All WNHS Staff

**Scope (Area):** Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

### Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and  
Breastfeeding](#)

### Restrictions

[Formulary: Restricted](#)

[HIGH RISK Medication](#) 

### Medication Class

Opioid analgesic

### Presentation

Vial: 2mg

### Storage

Store at room temperature, below 25°C

**Schedule 8 Medication**

### Dose

**Patient-Controlled Intravenous Analgesia (PCIA)**

Refer to [Intravenous Patient-Controlled Analgesia in Labour – Medical](#)

### Administration

Refer to the [Australian Injectable Drugs Handbook](#)

## [Refer to Intravenous Patient-Controlled Analgesia in Labour – Medical](#)

### PCIA

Step 1 Reconstitution (applicable for vial only): Reconstitute the 2mg vial with 2 mL of Sodium Chloride 0.9% or Water for injections. Shake well to dissolve.

Step 2 Dilution: Dilute in 100mL Sodium Chloride 0.9%. Final concentration is 20 microgram/mL

Step 3 Administration: ONLY an anaesthetist should program the PCIA pump or adjust variables.

### Monitoring

Continuous maternal respiratory monitoring should be used. This includes: continuous pulse oximetry, continuous presence of a registered nurse/midwife or medical staff in the room, observation of conscious state and respiratory rate 30 minutely.

An oxygen source must be readily accessible and naloxone should be available within the labour and birth room.

### Pregnancy

**1<sup>st</sup> Trimester:** Considered safe to use

**2<sup>nd</sup> Trimester:** Considered safe to use

**3<sup>rd</sup> Trimester:** Considered safe to use

### Breastfeeding

Considered safe to use - Observe the breastfed infant for potential adverse effects such as drowsiness, poor feeding and sleeping pattern changes.

### Related Policies, Procedures & Guidelines

[Intravenous Patient-Controlled Analgesia in Labour – Medical](#)

[Gynaecology \(Non-Oncological\)](#)

[Intravenous Medications - Procedure for Reconstitution and Administration](#)

[Restricted Schedule 4 \(S4R\) and Schedule 8 \(S8\) Medications](#)

### References



Australian Medicines Handbook. Remifentanil. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Nov 10]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Remifentanyl, In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Nov 10]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Remifentanyl. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Nov 10]. Available from: <http://aidh.hcn.com.au>

Fiona Stanley Fremantle Hospital Group: [Remifentanyl Patient Controlled Intravenous Analgesia \(PCIA\)](#)

Fiona Stanley Fremantle Hospital Group: [Critical Care Guideline – Remifentanyl Infusion in ICU](#)

Keywords	Remifentanyl, PCIA, patient controlled intravenous analgesia, labour, opioid, analgesia, opioid				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:					
Date First Issued:	Aug 2015	Last Reviewed:	Nov 2021	Review Date:	Nov 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	Jan 2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance				
	<input checked="" type="checkbox"/>  Std 4: Medication Safety				
<b>Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.